Financial Ratios

GLENMARK PHARMACEUTICALS LTD.

NSE : GLENMARKBSE : 532296ISIN CODE : INE935A01035Industry : Pharmaceuticals & DrugsHouse : Glenmark
BSE1080.050.5 (+0.05 %)
PREV CLOSE ( ) 1079.55
OPEN PRICE ( ) 1081.30
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 13240
TODAY'S LOW / HIGH ( )1061.15 1088.35
52 WK LOW / HIGH ( )520.1 1095.95
NSE1079.35-0.95 (-0.09 %)
PREV CLOSE( ) 1080.30
OPEN PRICE ( ) 1085.00
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 1079.35 (7)
VOLUME 475440
TODAY'S LOW / HIGH( ) 1061.25 1088.75
52 WK LOW / HIGH ( )520.1 1096
Select year
ParticularsMar2023Mar2022Mar2021Mar2020Mar2019
Operational & Financial Ratios
   Earnings Per Share (Rs)42.8470.8058.4648.0052.74
   CEPS(Rs)49.3676.4663.8052.9156.51
   DPS(Rs)2.502.502.502.502.00
   Book NAV/Share(Rs)633.48593.12524.29468.25422.85
   Tax Rate(%)23.1014.5315.1411.7418.14
Margin Ratios
   Core EBITDA Margin(%)16.0418.7722.7019.4321.05
   EBIT Margin(%)19.3728.6126.5326.6832.39
   Pre Tax Margin(%)17.1225.9823.3422.8628.84
   PAT Margin (%)13.1622.2119.8020.1823.61
   Cash Profit Margin (%)15.1723.9821.6122.2425.29
Performance Ratios
   ROA(%)4.608.227.727.499.59
   ROE(%)6.9812.6711.7810.7713.34
   ROCE(%)8.5813.2512.5411.2414.36
   Asset Turnover(x)0.350.370.390.370.41
   Sales/Fixed Asset(x)2.963.063.062.772.60
   Working Capital/Sales(x)12.359.353.463.302.20
Efficiency Ratios
   Fixed Capital/Sales(x)0.340.330.330.360.38
   Receivable days103.04104.8294.75106.64171.25
   Inventory Days40.5834.7735.0647.5458.54
   Payable days221.36190.67198.46226.78254.34
Valuation Parameters
   PER(x)10.856.257.954.2912.24
   PCE(x)9.425.787.283.8911.42
   Price/Book(x)0.730.750.890.441.53
   Yield(%)0.540.570.541.210.31
   EV/Net Sales(x)1.971.982.211.393.35
   EV/Core EBITDA(x)6.587.007.314.8711.70
   EV/EBIT(x)9.106.267.575.1910.33
   EV/CE(x)0.600.630.730.471.28
   M Cap / Sales1.601.531.730.872.89
Growth Ratio
   Net Sales Growth(%)0.977.5812.746.4714.21
   Core EBITDA Growth(%)6.770.7119.655.9940.76
   EBIT Growth(%)-30.8816.4723.37-12.2972.31
   PAT Growth(%)-39.4921.1221.77-8.9971.89
   EPS Growth(%)-39.4921.1221.77-8.9971.89
Financial Stability Ratios
   Total Debt/Equity(x)0.180.220.250.270.26
   Current Ratio(x)1.151.201.611.682.25
   Quick Ratio(x)0.931.001.421.401.85
   Interest Cover(x)8.6010.908.316.999.12
   Total Debt/Mcap(x)0.240.290.280.610.17

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.